Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Opus Genetics (IRD) Accumulated Expenses (2019 - 2026)

Opus Genetics has reported Accumulated Expenses over the past 8 years, most recently at $4.9 million for Q1 2026.

  • Quarterly Accumulated Expenses fell 45.99% to $4.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $4.9 million through Mar 2026, down 45.99% year-over-year, with the annual reading at $4.5 million for FY2025, 44.91% down from the prior year.
  • Accumulated Expenses was $4.9 million for Q1 2026 at Opus Genetics, up from $4.5 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $9.1 million in Q1 2025 and troughed at $233000.0 in Q1 2023.
  • The 5-year median for Accumulated Expenses is $1.4 million (2025), against an average of $2.7 million.
  • Year-over-year, Accumulated Expenses crashed 83.58% in 2023 and then skyrocketed 1466.09% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $1.7 million in 2022, then plummeted by 55.29% to $753000.0 in 2023, then skyrocketed by 981.94% to $8.1 million in 2024, then crashed by 44.91% to $4.5 million in 2025, then increased by 9.58% to $4.9 million in 2026.
  • Per Business Quant, the three most recent readings for IRD's Accumulated Expenses are $4.9 million (Q1 2026), $4.5 million (Q4 2025), and $1.4 million (Q3 2025).